Meeder Asset Management’s AstraZeneca AZN Stock Holding History

Meeder Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,008	Closed	-$111K	–	889
2022 Q3	$111K	Buy	1,008 +53	+6%	+$6.72K	0.01%	667
2022 Q2	$126K	Sell	955 -303	-24%	-$39.8K	0.01%	689
2022 Q1	$167K	Buy	+1,258	New	+$151K	0.01%	691
2021 Q4	–	Sell	-1,646	Closed	-$198K	–	1258
2021 Q3	$198K	Buy	1,646 +1,444	+715%	+$168K	0.01%	725
2021 Q2	$24K	Buy	202 +193	+2,144%	+$21.2K	﹤0.01%	1397
2021 Q1	$1K	Hold	9	–	–	﹤0.01%	2174
2020 Q4	$1K	Hold	9	–	–	﹤0.01%	1596
2020 Q3	$1K	Buy	+9	New	+$1K	﹤0.01%	1927
2019 Q3	–	Sell	-945	Closed	-$78K	–	2139
2019 Q2	$78K	Buy	+945	New	+$74.1K	0.01%	821
2017 Q4	–	Sell	-1,540	Closed	-$104K	–	1654
2017 Q3	$104K	Hold	1,540	–	–	0.01%	555
2017 Q2	$105K	Buy	+1,540	New	+$101K	0.01%	552
2017 Q1	–	Sell	-1,692	Closed	-$92K	–	1653
2016 Q4	$92K	Buy	+1,692	New	+$96.1K	0.01%	536

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Meeder Asset Management's AZN Position: Q4 2022 in Review

Meeder Asset Management sold out of AstraZeneca (AZN) in Q4 2022, closing a stake of 1,008 shares — an estimated $111K sold.

Meeder Asset Management first reported a position in AZN in Q4 2016 and held it in 12 quarters. The position peaked at $198K in Q3 2021. 1,061 funds tracked by Wall St. Rank hold AZN as of Q4 2022.

Meeder Asset Management reported no remaining AstraZeneca position as of Q4 2022 after selling out during the quarter.
Meeder Asset Management sold 1,008 AstraZeneca shares in Q4 2022, an estimated $111K.
Meeder Asset Management first reported a position in AstraZeneca in Q4 2016 and held it in 12 quarters.
Meeder Asset Management's AstraZeneca position peaked at $198K in Q3 2021.
1,061 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2022.

Based on Meeder Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.